A recent Dermatology digest,
as sent to subscribers

Study Type: Cohort study

Key Question: What is the population prevalence of pathogenic variants in familial melanoma genes and their associated cancer risks when assessed without family history bias?

Key Findings:

• Combined prevalence of pathogenic variants in 8 familial melanoma genes was 0.5-0.9% in population cohorts (n=696,665)
• Prevalence exceeded 2.5% testing threshold in patients with multiple melanomas or melanoma diagnosed before age 40
• Novel cancer associations identified including BAP1 with prostate cancer, CDKN2A with breast/biliary tract cancers, and POT1 with myeloma

Clinical Relevance: This genome-first approach provides unbiased prevalence data that may inform when to offer germline testing for melanoma predisposition genes in UK practice, potentially expanding testing criteria beyond current family history-based guidelines.

Limitations: The cohorts were predominantly of European ancestry, limiting generalisability to diverse UK populations.

Study Type: Prospective case series

Key Question: Does neoadjuvant capecitabine provide effective tumour downstaging in advanced cutaneous squamous cell carcinoma of the head and neck?

Key Findings:

• Clinical tumour regression occurred in 10/15 patients (67%) following two cycles of capecitabine
• Complete pathologic response achieved in 5/12 patients (42%) who proceeded to surgery
• No grade 3+ toxicities reported; treatment well-tolerated in elderly population (mean age 77 years)

Clinical Relevance: Offers potential bridging therapy for advanced head and neck cutaneous SCC while patients await definitive surgery, particularly relevant given NHS waiting time pressures and aging population demographics.

Limitations: Small case series without control group limits generalisability of findings.

Study Type: Narrative review

Key Question: What does current epidemiological evidence reveal about atopic dermatitis patterns, burden, and risk factors across the lifespan?

Key Findings:

• AD affects approximately 129 million people globally, with substantial disease burden extending well beyond childhood
• Longitudinal studies reveal distinct disease trajectories with varying onset patterns, activity levels, and severity, plus significant adult-onset disease
• Environmental factors including diet, early antibiotic exposure, and climate/pollution exposures influence disease risk and progression

Clinical Relevance: UK dermatologists should recognise AD as a lifelong condition requiring age-appropriate management strategies, particularly given emerging evidence of significant adult-onset disease and environmental modifiable risk factors.

Limitations: As a narrative review, findings depend on the quality and selection of underlying studies rather than systematic evidence synthesis.

Study Type: Commentary/perspective article

Key Question: What are the outstanding challenges in atopic dermatitis management and where are future therapeutic innovations likely to emerge?

Key Findings:

• The abstract does not provide specific findings, challenges, or innovation areas - only states that significant challenges remain despite recent advances in epidemiology, pathogenesis, and therapeutics
• No quantitative data or specific research directions are mentioned in the provided abstract

Clinical Relevance: This perspective may inform UK dermatologists about emerging research priorities and therapeutic development pipelines for atopic dermatitis, the most common inflammatory skin condition.

Limitations: The abstract provides insufficient detail to assess the authors' specific recommendations or evidence base for their proposed future directions.

Note: This summary is based on a very brief abstract that lacks substantive content about the authors' actual perspectives or recommendations.

Study Type: Narrative review

Key Question: What are the current systemic therapy options for moderate-to-severe atopic dermatitis and how should clinicians select between them?

Key Findings:

• Dupilumab (IL-4 receptor antagonist) is approved from 6 months of age and provides additional benefits for comorbid asthma and eosinophilic oesophagitis
• Three additional biologics now approved for adolescents/adults: tralokinumab and lebrikizumab (both IL-13 inhibitors) and nemolizumab (IL-31 receptor inhibitor)
• JAK inhibitors (upadacitinib, abrocitinib, baricitinib) offer rapid pruritus relief but carry greater safety considerations than biologics

Clinical Relevance: This provides UK dermatologists with a current overview of expanding systemic treatment options for moderate-to-severe atopic dermatitis, relevant for specialist clinic decision-making and NICE pathway considerations.

Limitations: As a narrative review, this lacks systematic methodology and critical appraisal of the evidence base for treatment selection guidance.